Clinical trials: completed, sponsored by AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of…
- Trial name
- MIRANDA (NCT06040086)
- Testing
- Tozorakimab
- Where
- 368 sites in United States, Argentina and 27 more
- Volunteers
- 1,454 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Breast Cancer
'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
The objectives of this study are to assess safety and effectiveness of Lynparza tablet (olaparib, hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug according to the approved…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer
- Trial name
- OLAP (NCT04553926)
- Where
- 18 sites in South Korea
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia
ALICIA (Acalabrutinib in CLL Therapy)
This is a multicenter non-interventional observational study conducted with a single hand arm to collect real-world data. In this study, commercially available acalabrutinib will be used as prescribed treatment for CLL as per the…
- Trial name
- ALICIA (NCT04746950)
- Where
- 15 sites in Russia
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Asthma
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
- Trial name
- PASSAGE (NCT05329194)
- Testing
- Tezepelumab
- Where
- 37 sites in United States
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Asthma
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with asthma aged 4 to less than 12 years.
- Trial name
- COMPAIR (NCT07433569)
- Testing
- Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC]…
- Trial name
- NCT03519971
- Testing
- Durvalumab, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel
- Where
- 86 sites in Brazil, Czechia and 12 more
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or…
- Trial name
- COMETA (NCT06897748)
- Testing
- Tozorakimab
- Where
- 12 sites in Russia
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
The purpose of the study is to assess the effect of AZD5004 on the pharmacokinetics (PK) of mitiglinide and pioglitazone in healthy participants.
- Trial name
- NCT07444424
- Testing
- AZD5004, Mitiglinide, Pioglitazone
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Arterial Hypertension, Chronic Kidney Disease
PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia
This study is a multi-centre, non-interventional, observational, prospective study with retrospective analysis. The main purpose of the study is to describe the rate of CKD diagnosis in patients with AH and CKD markers.
- Trial name
- PRIORITY-CKD (NCT06372431)
- Where
- 30 sites in Russia
- Volunteers
- 9,914 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia
This is a multicenter observational retrospective-prospective study consisting of retrospective and prospective phases. Trial will include 2 visits for obtaining the patient's demographic and clinical data: the 1st is…
- Trial name
- SEVERUS (NCT06759519)
- Where
- 32 sites in Russia
- Volunteers
- 637 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
The purpose of this study is to characterize andexanet posology and interaction between andexanet and enoxaparin post infusion in healthy participants.
- Trial name
- NCT07312851
- Testing
- Andexanet alfa, Rivaroxaban, Apixaban
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Ovarian Cancer, Prostate Cancer
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites.
- Trial name
- NCT04560452
- Where
- 37 sites in China
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Unresectable Breast Cancer, Metastatic Breast Cancer
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
Trastuzumab deruxtecan (T-DXd) has been studied in multiple global prospective DESTINY-Breast trials and has a marketing authorization from Health Canada for patients with HER2-positive metastatic breast cancer (mBC) and HER2-low…
- Conditions
- Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-positive Breast Cancer
- Trial name
- HER-TEMPO (NCT06386263)
- Testing
- Trastuzumab deruxtecan
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Chronic Heart Failure
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF).
- Trial name
- LUMINARA (NCT06299826)
- Testing
- AZD5462
- Where
- 57 sites in United States, Bulgaria and 8 more
- Volunteers
- 375 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels
The purpose of this study is to evaluate pharmacodynamics (PD) of AZD0780 compared with placebo by assessment of low-density lipoprotein-cholesterol (LDL-C) levels following repeated oral dosing in healthy adults with elevated…
- Trial name
- NCT07423598
- Testing
- AZD0780
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Liver Fibrosis, Hepatic Cirrhosis
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis.
- Trial name
- BORANA (NCT06750276)
- Testing
- AZD2389
- Where
- 9 sites in United States, Puerto Rico and 1 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Asthma
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
- Trial name
- LOGOS (NCT04609904)
- Testing
- BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg
- Where
- 317 sites in United States, Brazil and 14 more
- Volunteers
- 2,187 people
- Sponsor
- AstraZeneca
Hematological Malignancies
Study of AZD9829 in CD123+ Hematological Malignancies
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
- Trial name
- NCT06179511
- Testing
- AZD9829
- Where
- 22 sites in United States, Australia and 8 more
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Asthma
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
- Trial name
- KALOS (NCT04609878)
- Testing
- BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg
- Where
- 360 sites in United States, Argentina and 19 more
- Volunteers
- 2,274 people
- Sponsor
- AstraZeneca
Prostate Cancer
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).
- Trial name
- ASCERTAIN (NCT05938270)
- Testing
- Saruparib (AZD5305), Darolutamide, No Treatment
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 113 people
- Sponsor
- AstraZeneca